Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokinetics and...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacol Res Perspect
Main Authors: Dayal, Satish, Aluri, Jagadeesh, Hall, Nancy, Filippov, Gleb, Moline, Margaret, Reyderman, Larisa, Landry, Ishani
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2021
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8023329/
https://ncbi.nlm.nih.gov/pubmed/33822479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.758
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items